AstraZeneca PLC (AZN)vsScienture Holdings, Inc. (SCNX)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
SCNX
Scienture Holdings, Inc.
$0.39
+5.08%
HEALTHCARE · Cap: $15.56M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 13609177% more annual revenue ($58.74B vs $431,610). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SCNX
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+15.5%
Fair Value
$0.53
Current Price
$0.39
$0.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 1870.0%
Revenue surging 810.0% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -55.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : SCNX
The strongest argument for SCNX centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 810.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : SCNX
The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while SCNX is a hypergrowth play — different risk/reward profiles.
SCNX is growing revenue faster at 810.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 43/100), backed by strong 17.4% margins. SCNX offers better value entry with a 15.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Scienture Holdings, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Scienture Holdings, Inc. (SCNX) is a biotechnology company dedicated to advancing therapeutic solutions for neurological disorders through its innovative drug development pipeline. Leveraging cutting-edge technology and a highly proficient research team, Scienture aims to address significant unmet medical needs while enhancing patient outcomes. The company's unwavering commitment to scientific excellence, regulatory adherence, and strategic partnerships not only fuels its growth prospects but also underscores its potential to deliver impactful contributions to global healthcare advancements. As the healthcare sector continues to expand, SCNX is well-positioned to capitalize on emerging opportunities in the neurological treatment landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?